Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients.
Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients.
复制标题
DOI：
10.1634/theoncologist.2016-0483
复制
发表时间：
2017-11
期刊：
影响因子：
--
通讯作者：
Gumà J
中科院分区：
文献类型：
--
作者：
Guaita-Esteruelas S;Saavedra-García P;Bosquet A;Borràs J;Girona J;Amiliano K;Rodríguez-Balada M;Heras M;Masana L;Gumà J
循环中的FABP 4和FABP 5可能是乳腺癌的生物标志物。这篇文章的重点是FABP 4和FABP 5血浆水平与乳腺癌的存在的关联。脂肪组织是一种内分泌器官，可通过其分泌的脂肪因子在肿瘤进展中发挥作用。脂肪源性脂肪酸结合蛋白（FABP）4和FABP 5在乳腺癌中的作用目前正在研究中，但其在这种病理学中的循环水平知之甚少。我们分析了乳腺癌患者FABP 4和FABP 5的血液浓度，以确定它们与乳腺癌之间是否存在关联。我们研究了294名有乳腺癌家族史的肿瘤科女性;其中198名女性患有乳腺癌，96名为健康对照。测定FABP 4、FABP 5、血脂、标准生化参数和高敏C反应蛋白（hsCRP）水平。我们分析了FABP 4和FABP 5与乳腺癌的相关性，同时调整了人口统计学，人体测量学和生化参数。乳腺癌患者FABP 4和FABP 5的血液浓度分别高出24.8%（p <0.0001）和11.4%（p <0.05）。在乳腺癌患者中，脂肪酸结合蛋白4与年龄、体重指数（BMI）、FABP 5、极低密度脂蛋白胆固醇（VLDL c）、胆固醇中非高密度脂蛋白（non-HDL c）、载脂蛋白B 100（ApoB 100）、甘油三酯、甘油、葡萄糖和hsCRP呈正相关（p < .05），与HDL c呈负相关（p < .005）。在乳腺癌患者中，脂肪酸结合蛋白5与BMI、FABP 4、VLDLc、甘油三酯、甘油和hsCRP呈正相关（p < .05），与HDLc和载脂蛋白AI（ApoAI）呈负相关（p < .05）。使用logistic回归分析并调整年龄、BMI、hsCRP、非HDL c和甘油三酯，FABP 4与乳腺癌独立相关（比值比[OR]：1.091 [95% CI：1.037-1.149]）。此外，乳腺癌患者的总胆固醇、VLDLc、非HDLc、ApoB 100、甘油三酯和hsCRP显著升高（p <0.005）。相比之下，乳腺癌患者的非酯化脂肪酸浓度显著降低（p <0.05）。与对照组相比，乳腺癌患者的循环FABP 4和FABP 5水平升高。在调整重要协变量后，FABP 4与乳腺癌的正相关性得以维持，而与FABP 5的相关性则消失。我们的数据强化了脂肪组织及其脂肪因子在乳腺癌中的作用。尽管有这些数据，但必须进行进一步的研究，以更好地解释这些血液参数的预后或诊断价值及其在乳腺癌中的可能作用。我们专注于脂肪组织对癌症的影响，这一点越来越受到认可。脂肪细胞衍生的脂肪因子与乳腺癌之间的关联开辟了新的诊断和治疗前景。在这项研究中，我们提供了有关乳腺癌患者FABP 4和FABP 5血浆浓度的原始数据。与对照组相比，乳腺癌患者显示出更高的FABP 4和FABP 5血液水平。我们的数据表明，特别是循环中的FABP 4水平可以被认为是一种新的独立的乳腺癌生物标志物。我们的工作将基础科学数据转化为临床，将脂肪组织和脂质代谢与乳腺癌之间的关系联系起来。
Circulating FABP4 and FABP5 may be a biomarker for breast cancer. This article focuses on the association of FABP4 and FABP5 plasma levels with the presence of breast cancer. Adipose tissue is an endocrine organ that could play a role in tumor progression via its secreted adipokines. The role of adipose‐derived fatty acid‐binding protein (FABP) 4 and FABP5 in breast cancer is presently under study, but their circulating levels in this pathology are poorly known. We analyzed the blood concentrations of FABP4 and FABP5 in breast cancer patients to determine whether there is an association between them and breast cancer. We studied 294 women in the oncology department with a family history of breast cancer; 198 of the women had breast cancer, and 96 were healthy controls. The levels of FABP4, FABP5, lipid profile, standard biochemical parameter, and high‐sensitivity C‐reactive protein (hsCRP) were determined. We analyzed the association of FABP4 and FABP5 with breast cancer, while adjusting for demographic, anthropometric, and biochemical parameters. Breast cancer patients had a 24.8% (p < .0001) and 11.4% (p < .05) higher blood concentration of FABP4 and FABP5, respectively. Fatty acid‐binding protein 4 was positively associated with age, body mass index (BMI), FABP5, very‐low‐density lipoprotein cholesterol (VLDLc), non‐high‐density lipoprote in cholesterol (non‐HDLc), Apolipoprotein B 100 (ApoB100), triglycerides, glycerol, glucose, and hsCRP (p < .05), and was negatively associated with HDLc (p < .005) in breast cancer patients. Fatty acid‐binding protein 5 was positively associated with BMI, FABP4, VLDLc, triglycerides, glycerol, and hsCRP (p < .05), and was negatively associated with HDLc and Apolipoprotein AI (ApoAI) (p < .05) in breast cancer patients. Using a logistic regression analysis and adjusting for age, BMI, hsCRP, non‐HDLc, and triglycerides, FABP4 was independently associated with breast cancer (odds ratio [OR]: 1.091 [95% CI: 1.037–1.149]). Moreover, total cholesterol, VLDLc, non‐HDLc, ApoB100, triglycerides, and hsCRP were significantly increased in breast cancer patients (p < .005). In contrast, the non‐esterified fatty acids concentrations were significantly decreased in breast cancer patients (p < .05). Circulating FABP4 and FABP5 levels were increased in breast cancer patients compared with controls. The positive association of FABP4 with breast cancer was maintained after adjusting for important covariates, while the association with FABP5 was lost. Our data reinforce the role of adipose tissue and their adipokines in breast cancer. Despite these data, further studies must be performed to better explain the prognosis or diagnostic value of these blood parameters and their possible role in breast cancer. We focus on the effect of adipose tissue on cancer, which is increasingly recognized. The association between adipocyte‐derived adipokines and breast cancer opens new diagnosis and therapy perspectives. In this study, we provide original data concerning FABP4 and FABP5 plasma concentrations in breast cancer patients. Compared to control group, breast cancer patients show higher FABP4 and FABP5 blood levels. Our data suggest that, particularly, circulating FABP4 levels could be considered a new independent breast cancer biomarker. Our work translates basic science data to clinic linking the relationship between adipose tissue and lipid metabolism to breast cancer.